Healthy Clinical Trial
— MystHypOfficial title:
A Neurophenomenological Study of Hypnosis
Mystical experience is described as an experience that is unique to everyone, potentially transformative and leaving a mark for many years or even a lifetime. It is characterized by: a loss of self/ego, being with the whole/nature/universe, transcendence, a loss of spatio-temporal reference points, ineffability, peace and joy, a sacred character, and a noetic quality. The mystical experience is one that occurs in the context of non-ordinary states of consciousness such as meditation and the consumption of so-called psychedelic drugs, for example. It would seem, in fact, to correspond to the transformative mechanism of the psychedelic experience. The goal ofthis study is to investigate the possibility of a mystical experience through hypnosis.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | January 31, 2025 |
Est. primary completion date | September 30, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - at least 18 years old - good comprehension of French Exclusion Criteria: - Psychiatric history - History of neurological disorder - Psychoactive medication - Addiction - Alcoholism |
Country | Name | City | State |
---|---|---|---|
Belgium | University of Liege | Liège |
Lead Sponsor | Collaborator |
---|---|
University of Liege |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Socio-demographics | age, sex, éducation, nationality, prior practice of hypnosis or other non-ordinary states of consciousness, prior mystical experience. | At screening | |
Other | Psychiatric screening | Psychiatric screening will be assessed with the Mini-International Neuropsychiatric Interview | At screening | |
Other | Beliefs about hypnosis | Beliefs about hypnosis will be assessed with an open-ended question "What are your beliefs about hypnosis?" | Before the procedure | |
Other | Expectancies about the study | Expectancies about the study will be assessed with an open-ended question "What are your expectancies about the study?" | Before the procedure | |
Other | Phenomenal control | The phenomenal control will be assessed with the Phenomenological Control Scale. | During the procedure | |
Other | Positive and negative affects | Positive and negative affects will be assessed with the Positive Affect and Negative Affect. | Beforethe procedure, During the procedure, direcly after the procedure, and after 3 months | |
Other | Absorption trait | The absorption trait will be assessed with the Tellegen Absorption Scale which consists of 34 true/false items, aiming to measure the absorption of a person, meaning the disposition for having episodes of a deep involvement that engage all the subject's resources (perceptual, imaginative, and cognitive). The total score range is from 0 to 34. The higher the score, the more one has a high propensity for absorption. | Before the procedure | |
Other | Dissociation trait | The dissociation trait will be assessed with the Dissociative Experience Scale. It is a self-reported questionnaire used to evaluate the presence, quantity, and type of dissociative experiences one might live in daily life. It consists of 28 items arranged on an analog scale (from 0 to 100% measuring the frequency of dissociative experiences), and the total score ranges from 0 to 100. There is a cutoff of 45 as a mean score to suggest a dissociative disorder. This questionnaire is not a diagnostic instrument; it is designed only for screening, but it can suggest that a specific clinical assessment is needed. | Before the procedure | |
Other | Anxiety state | Anxiety will be assessed with a numerical rating scale. | Before the procedure and during the procedure | |
Other | Absorption state | Absorption will be assessed with a numerical rating scale. | During the procedure | |
Other | Dissociation state | Dissociation will be assessed with a numerical rating scale. | During the procedure | |
Other | Alertness | Alertness will be assessed with a numerical rating scale. | During the procedure | |
Other | Time perception | We will ask the participants how long they thought the intervention lasted. | During the procedure | |
Other | Near Death Experience | The near death experience will be assessed with the The Near-Death Experience Content (NDE-C) Scale. | During the procedure | |
Primary | Mystical experience | The 30-item revised Mystical Experience Questionnaire will assess the occurrence and intensity of mystical-type experiences. It is comprised of four factors: mysticality, positivity of mood, transcendence of time and space, and ineffability. A mystical experience is defined as having a score equal or above 60% on all factors. | During the procedure | |
Primary | Hypnotizability | The susceptibility one has concerning hypnosis. Will be assessed with the Elkins Hypnotizability Scale. A score :
0-3 : low hypnotizability 4-7: medium hypnotizability 8-11 : high hypnotizability 12 : very high hypnotizability. |
During the procedure | |
Secondary | Ego Dissolution | The Ego Dissolution Inventory will assess the occurrence of ego dissolution. | During the procedure | |
Secondary | Alteration of consciousness | The Phenomenology of Consciousness Inventory will allow to empirically quantify the subjective experience in terms of pattern and intensity parameters. It is composed of 53 items consisting of 12 major dimensions (e.g., positive affect), and 14 minor dimensions (e.g., absorption) (annex). Graphs will be constructed to represent the intensity and pattern of relationships between pairs of dimensions. | During the procedure | |
Secondary | Psychological flexibility | Multidimensional Psychological Flexibility Inventory. | Before the procedure and direclty after the procedure | |
Secondary | Cognitive flexibility | Cognitive flexility will be assessed with the Test of Attentional Performance which is an informatized cognitive task. | Before the procedure and direclty after the procedure | |
Secondary | Psychological well-being | Psychological well-being will be assessed with the Warwick-Edinburgh Mental Well-Being Scale | Before the intervention and after 3 months | |
Secondary | Modification of mood, cognition, emotion and behavior | We will ask an open-ended question "Since the experimental session, have you observed any changes in your behaviors, emotions and beliefs? If so, can you tell us about them?". | After 3 months | |
Secondary | Phenomenal experience | Phenomenal experience will be assessed by the recording of the narrative experience. | During the procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |